Evaluation of Quercetin in Type 2 Diabetes: Impact on Glucose Tolerance and Postprandial Endothelial Function.

Trial Profile

Evaluation of Quercetin in Type 2 Diabetes: Impact on Glucose Tolerance and Postprandial Endothelial Function.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2015

At a glance

  • Drugs Quercetin (Primary) ; Acarbose
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 17 Mar 2015 Planned End Date changed from 1 Apr 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.
    • 17 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Feb 2014 Planned End Date changed from 1 Sep 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top